Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 20, 2024 - Issue
Submit an article Journal homepage
97
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study

Benfa Gong1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-5557-7291View further author information
ORCID Icon,
Li-Jen Cheng2 Medical Affairs, Astellas Pharma Singapore Pte. Ltd, SingaporeView further author information
,
Christopher H Young3 Advanced Informatics & Analytics, Astellas Pharma US Inc., Northbrook, IL, USAView further author information
,
Prabhuram Krishnan2 Medical Affairs, Astellas Pharma Singapore Pte. Ltd, SingaporeView further author information
,
Ying Wang1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Hui Wei1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Chunlin Zhou1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Shuning Wei1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Yan Li1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Qiuyun Fang1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Jia Zhong4 Analysis Group, Inc., Beijing, People’s Republic of ChinaView further author information
,
Eric Q Wu5 Analysis Group, Inc., Boston, MA, USAView further author information
,
Yingchang Mi1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
&
Jianxiang Wang1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9437-9151View further author information
ORCID Icon show all
Pages 59-73 | Received 15 Aug 2023, Accepted 18 Dec 2023, Published online: 13 Feb 2024

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.